Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Grows By 437.3%

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the recipient of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 631,300 shares, a growth of 437.3% from the January 15th total of 117,500 shares. Based on an average daily volume of 3,650,000 shares, the short-interest ratio is presently 0.2 days. Approximately 3.6% of the shares of the stock are sold short.

Institutional Investors Weigh In On Virpax Pharmaceuticals

A hedge fund recently bought a new stake in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC acquired a new stake in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned approximately 1.17% of Virpax Pharmaceuticals at the end of the most recent reporting period. 32.23% of the stock is currently owned by hedge funds and other institutional investors.

Virpax Pharmaceuticals Price Performance

VRPX stock opened at $0.29 on Friday. The company’s 50-day moving average price is $0.33 and its 200 day moving average price is $0.59. Virpax Pharmaceuticals has a 52 week low of $0.23 and a 52 week high of $5.48.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.